Jaguar Health Inc
NASDAQ:JAGX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Eolus Vind AB (publ)
STO:EOLU B
|
SE |
Jaguar Health Inc
Other Current Assets
Jaguar Health Inc
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Jaguar Health Inc
NASDAQ:JAGX
|
Other Current Assets
$9.1m
|
CAGR 3-Years
7%
|
CAGR 5-Years
31%
|
CAGR 10-Years
34%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Current Assets
$4.2B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
7%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Current Assets
$1.5B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
6%
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Current Assets
$2.8B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-5%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Current Assets
$9.6B
|
CAGR 3-Years
14%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Current Assets
$14.5B
|
CAGR 3-Years
70%
|
CAGR 5-Years
38%
|
CAGR 10-Years
37%
|
|
Jaguar Health Inc
Glance View
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The company is headquartered in San Francisco, California and currently employs 52 full-time employees. The company went IPO on 2015-05-13. The firm is focused on developing plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with gastrointestinal (GI) distress, including chronic and debilitating diarrhea. The firm operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. Its Canalevia-CA1 is used for chemotherapy-induced diarrhea in dogs. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. Its wholly owned subsidiary is Napo Pharmaceuticals, Inc.
See Also
What is Jaguar Health Inc's Other Current Assets?
Other Current Assets
9.1m
USD
Based on the financial report for Dec 31, 2025, Jaguar Health Inc's Other Current Assets amounts to 9.1m USD.
What is Jaguar Health Inc's Other Current Assets growth rate?
Other Current Assets CAGR 10Y
34%
Over the last year, the Other Current Assets growth was -26%. The average annual Other Current Assets growth rates for Jaguar Health Inc have been 7% over the past three years , 31% over the past five years , and 34% over the past ten years .
